Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

89bio, Inc. - Common Stock (NQ:ETNB)

14.76 -0.01 (-0.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 89bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease
89bio Inc (NASDAQ: ETNB) announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in  
Via Benzinga
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
From 89bio, Inc.
Via GlobeNewswire
Analyst Ratings for 89bio
 
Via Benzinga
Analyst Expectations for 89bio's Future
 
Via Benzinga
The Latest Analyst Ratings for 89bio
 
Via Benzinga
Analyst Ratings for 89bio
 
Via Benzinga
89bio's Fatty Liver Candidate Shows Long-Term Improvement: Details
89bio Inc (NASDAQ: ETNB) released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with  
Via Benzinga
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
From 89bio, Inc.
Via GlobeNewswire
89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
From 89bio, Inc.
Via GlobeNewswire
Why Shares of 89bio Plummeted on Tuesday
So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors. 
Via The Motley Fool
Akero Therapeutics' Disappointing NASH Data Drags Its Rival
Earlier today, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. 
Via Benzinga
Why Akero Therapeutics Stock Is Crashing Today
Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX). 
Via The Motley Fool
PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
US Stocks Gain; PepsiCo Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.19% to 33,668.96 while the NASDAQ rose 0.16%... 
Via Benzinga
Topics Stocks
Why Akero Therapeutics Lost More Than Half Its Value, And Dragged Down 89bio
Both companies are working on treatments for NASH. But Akero's disappointed in a midstage test. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the 2023 Cantor Global Healthcare Conference
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From 89bio, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
 
Via Benzinga
89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.